Aggressive pituitary adenomas-diagnosis and emerging treatments

Nature Reviews Endocrinology

Volumn 10, Issue 7, 2014, Pages 423-435

  Di Ieva, Antonio ^a   Rotondo, Fabio ^a   Syro, Luis V ^b   Cusimano, Michael D ^a   Kovacs, Kalman ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMA; DACARBAZINE; HUMANS; KI-67 ANTIGEN; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903168307     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.64     Document Type: Review

References (143)

1. Asa, S. L. & Ezzat, S. The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4, 97-126 (.2009
2. Aflorei, E. D. & Korbonits, M. Epidemiology and etiopathogenesis of pituitary adenomas. J. Neurooncol. http://dx.doi.org/10.1007/s11060-013-1354- 1355.
3. Scheithauer, B. W., Kovacs, K. T., Laws, E. R. Jr & Randall, R. V. Pathology of invasive pituitary tumors with special reference to functional classification. J. Neurosurg. 65, 733-744 (.1986
4. Thapar, K. et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody. Neurosurgery 38, 99-106 (.1996
5. Meij, B. P., Lopes, M. B., Ellegala, D. B., Alden, T. D. & Laws, E. R. Jr. The long-Term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J. Neurosurg. 96, 195-208 (.2002
6. Kaltsas, G. A. et al. Diagnosis and management of pituitary carcinomas. J. Clin. Endocr. Metab. 90, 3089-3099 (.2005
7. Buchfelder, M. Management of aggressive pituitary adenomas: Current treatment strategies. Pituitary 12, 256-260 (.2009
8. McCormack, A. I., Wass, J. A. & Grossman, A. B. Aggressive pituitary tumours: The role of temozolomide and the assessment of MGMT status. Eur. J. Clin. Invest. 41, 1133-1148 (.2011
9. Raverot, G. et al. Pituitary carcinomas and aggressive pituitary tumours: Merits and pitfalls of temozolomide treatment. Clin. Endocrinol. (.Oxf.) 76, 769-775 (.2012
10. Lloyd, R V. et al. in Pathology and Genetics of Tumours of Endocrine Organs (.eds DeLellis, R. A. et al.) 10-13 (.IARC Press, 2004
11. Saeger, W. et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 156, 203-216 (.2007
12. Zada, G. et al. Atypical pituitary adenomas: Incidence, clinical characteristics, and implications. J. Neurosurg. 114, 336-344 (.2011
13. Scheithauer, B W. et al. in Pituitary Carcinoma (.eds DeLellis, R. A. et al.). 36-39 (.IARC Press, 2004
14. Melmed, S. Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7, 257-266 (.2011
15. Hardy, J. Transsphenoidal microsurgery of the normal and pathological pituitary. Clin. Neurosurg. 16, 185-217 (.1969
16. Campero, A., Martins, C., Yasuda, A. & Rhoton, A. L. Jr. Microsurgical anatomy of the diaphragm sellae and its role in directing the pattern of growth of pituitary adenomas. Neurosurgery 62, 717-723 (.2008
17. Di Ieva, A. et al. The subdiaphragmatic cistern: Historic and radioanatomic findings. Acta Neurochir. (Wien) 154, 667-674 (2012
18. Knosp, E., Steiner, E., Kitz, K. & Matula, C. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33, 610-617 (.1993
19. Cusimano, M. D. et al. Outcomes of surgically treated giant pituitary tumours. Can. J. Neurol. Sci. 39, 446-457 (.2012
20. Delgrange, E., Trouillas, J., Maiter, D., Donckier, J. & Tourniaire, J. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82, 2012-2107 (.1997
21. Heaney, A. P. Clinical review: Pituitary carcinoma: Difficult diagnosis and treatment. J. Clin. Endocrinol. Metab. 96, 3649-3660 (.2011
22. Delgrange, E., Sassolas, G., Perin, G. & Trouillas, J. M. Clinical and histological correlations in prolactinomas, with specific reference to bromocriptine resistence. Acta Neurochir. (Wien.) 147, 4721-4727 (2005
23. Colao, A., Grasso, L. F., Pivonello, R. & Lombardi, G. Therapy of aggressive pituitary tumors. Expert Opin. Pharmacother. 12, 1561-1570 (.2011
24. George, D. H. et al Crooke's cell adenoma of the pituitary: An aggressive variant of corticotroph adenoma. Am. J. Surg. Pathol. 27, 1330-1336 (.2003
25. Kovacs, K. et al. Prognostic indicators in an aggressive pituitary Crooke's cell adenoma. Can. J. Neurol. Sci. 32, 540-545 (.2005
26. Crooke, A. A change in the basophil cells of the pituitary gland common to conditions which exhibit the syndrome attributed to basophil adenoma. J. Pathol. Bacteriol. 41, 339-349 (.1935
27. Scheithauer, B. W. et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47, 723-729 (.2000
28. Jahangiri, A. et al. A comprehensive long-Term retrospective analysis of silent corticotrophic adenomas versus hormone-negative adenomas. Neurosurgery 73, 8-17 (.2013
29. Asa, S. L., Ezzat, S., Watson, R. E., Lindell, E. P. & Horvath, E. in Tumors of Endocrine Organs (eds DeLellis, R. et al.) 30-32 (IARC Press, 2004
30. Mete, O., Ezzat, S. & Asa, S. L. Biomarkers of aggressive pituitary adenomas. J. Mol. Endocrinol. 49, R69-R78 (.2012
31. Mete, O. & Asa, S. L. Clinicopathological correlations in pituitary adenomas. Brain Pathology 22, 443-453 (.2012
32. Mete, O. & Asa, S. L. Therapeutic implications of accurate classification of pituitary adenomas. Semin. Diagn. Pathol. 30, 158-164 (.2013
33. Batisse, M. et al. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest. 31, 190-196 (.2013
34. Vieira Neto, L. et al. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr. Pract. 19, e145-e149 (.2013
35. Asa, S. L. et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 67, 7505-7511 (.2007
36. Sano, T., Ohshima, T. & Yamada, S. Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol. Res. Pract. 187, 530-533 (.1991
37. Hagiwara, A. et al. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: Imaging characteristics and pathologic correlation. Radiology 228, 533-538 (.2003
38. Wierinckx, A. et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr. Relat. Cancer 14, 887-900 (.2007
39. Trouillas, J. et al. A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126, 123-135 (.2013
40. Raverot, G., Jouanneau, E. & Trouillas, J. Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur. J. Endocrinol. 170, R121-R132 (.2014
41. Monsalves, E. et al. Growth patterns of pituitary adenomas and histopathological correlates. J. Clin. Endocrinol. Metab. 99, 1330-1338 (.2014
42. Salehi, F. et al. Biomarkers of pituitary neoplasms: A review (.Part II). Neurosurgery 67, 1790-1798 (.2010
43. Sav, A., Rotondo, F., Syro, L. V., Scheithauer, B. W. & Kovacs, K. Biomarkers of pituitary neoplasms. Anticancer Res. 32, 4639-4654 (.2012
44. Salehi, F. et al. Ki-67 in pituitary neoplasms: A review (.Part I). Neurosurgery 65, 429-437 (.2009
45. Chiloiro, S. et al. Radically resected pituitary adenomas: Prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary http://dx.doi.org/10.1007/s11102-013-0500-0506.
46. Kovacs, K. The 2004 WHO classification of pituitary tumors: Comments. Acta Neuropathol. 111, 62-63 (.2006
47. Turner, H E. & Wass, J. A. Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1, 147-151 (.1999
48. Thapar, K., Scheithauer, B. W., Kovacs, K., Pernicone, P. J. & Laws, E. R. Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 38, 765-770 (.1996
49. Kontogeorgos, G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83, 179-188 (.2006
50. Gejman, R., Swearingen, B. & Hedley-Whyte, E. T. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum. Pathol. 39, 758-766 (.2006
51. Trouillas, J. et al. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J. Neurosurg. 98, 1084-1093 (.2003
52. Jaffe, C. A. & Barkan, A. L. Acromegaly. Recognition and treatment. Drugs 47, 425-445 (.1994
53. LeRiche, V. K., Asa, S.L & Ezzat, S. Epidermal growth factor and its receptors (.EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J. Clin. Endocrinol. Metab. 81, 656-662 (.1996
54. Mete, O. et al. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr. Pathol. 24, 191-198 (.2013
55. Asa, S. L. & Ezzat, S. Genetics and proteomics of pituitary tumors. Endocrine 28, 43-47 (.2005
56. Lloyd, R. V., Vidal, S., Horvath, E, Kovacs, K. & Scheithauer, B. Angiogenesis in normal and neoplastic pituitary tissues. Microsc. Res. Tech. 60, 244-250 (.2003
57. Jugenburg, M., Kovacs, K., Stefaneanu, L. & Scheithauer, B. W. Vasculature in non-Tumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphological study. Endocr. Pathol. 6, 115-124 (.1995
58. Turner, H. E. et al. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J. Endocrinol. 165, 475-481 (.2000
59. Vidal, S. et al. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 438, 595-602 (.2001
60. Di Ieva, A. et al. Euclidean and fractal geometry of microvascular networks in normal and neoplastic pituitary tissue. Neurosurg. Rev. 31, 271-281 (.2008
61. Di Ieva, A. et al. Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. J. Anat. 211, 673-680 (.2007
62. Di Ieva, A. et al. Microvascular morphometrics of the hypohysis and pituitary tumors: From bench to operating theatre. Microvasc. Res. 89, 7-14 (.2013
63. Zachary, I. VEGF signalling: Integration and multi-Tasking in endothelial cell biology. Biochem. Soc. Trans. 31, 1171-1177 (.2003
64. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (.2011
65. Sánchez-Ortiga, R. et al. Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 16, 370-377 (.2013
66. Pan, L. X., Chen, Z. P., Liu, Y. S. & Zhao, J. H. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J. Neurooncol. 74, 71-76 (.2005
67. Yarman, S. et al. Expression of Ki-67, p53 and vascular endothelial growth factor (.VEGF) concomitantly in growth hormone-secreting pituitary adenomas: Which one has a role in tumor behavior? Neuro. Endocrinol. Lett. 31, 823-828 (.2010
68. Bisht, S., Feldmann, G. & Brossart, P. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. Expert Opin. Drug Metab. Toxicol. 9, 777-788 (.2013
69. Barroso-Sousa, R. et al. Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH syndrome. Thyroid http://dx.doi.org/10.1089/thy.2013.0571.
70. Jia, W. et al. Vascular endothelial growth inhibitor (.VEGI) is an independent indicator for invasion in human pituitary adenomas. Anticancer Res. 33, 3815-3822 (.2013
71. Kaur, B. et al. Hypoxia and the hypoxia-factor pathway in glioma growth and angiogenesis. Neuro. Oncol. 7, 134-153 (.2005
72. Scherpereel, A. et al. Overexpression of endocan induces tumor formation. Cancer Res. 63, 6084-6089 (.2003
73. Maurage, C. A. et al. Endocan expression and localization in human glioblastomas. J. Neuropathol. Exp. Neurol. 68, 633-641 (.2009
74. Sarrazin, S. et al. Endocan or endothelial cell specific molecule-1 (.ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta 1765, 25-37 (.2006
75. Cornelius, A. et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 22, 757-764 (.2012
76. McCabe, C. J. et al. Vascular endothelial growth factor, its receptor KDR/FLK-1, and pituitary transforming gene in pituitary tumors. J. Clin. Endocrinol. Metab. 87, 4238-4244 (.2002
77. Minematsu, T. et al. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr. Pathol. 17, 143-153 (.2006
78. Chesnokova, V. & Melmed, S. Pituitary tumour-Transforming gene (.PTTG) and pituitary senescence. Horm. Res. 71 (.Suppl. 2), 82-87 (.2009
79. Chesnokova, V. & Melmed, S. Pituitary senescence: The evolving role of PTTG. Mol. Cell Endocrinol. 326, 55-59 (.2010
80. Karga, H. J., Alexander, J. M., Hedley-Whyte, E. T., Klibanski, A. & Jameson, J. L. Ras mutations in human pituitary tumors. J. Clin. Endocr. Metab. 74, 914-919 (.1992
81. Cai, W. Y. et al. Ras mutations in human prolactinomas and pituitary carcinomas. J. Clin. Endocrinol. Metab. 78, 89-93 (.1994
82. Pei, L., Melmed, S., Scheithauer, B., Kovacs, K. & Prager, D. H-ras mutations in human pituitary carcinoma metastases. J. Clin. Endocrinol. Metab. 78, 842-846 (.1994
83. Rickert, C. H. et al. Increased chromosomal imbalances in recurrent pituitary adenomas. Acta Neuropathol. 102, 615-620 (.2001
84. Pack, S. D. et al. Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 43, 72-82 (.2005
85. Raverot, G. et al. Prognostic factors in prolactin pituitary tumors: Clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J. Clin. Endocrinol. Metab. 95, 1708-1716 (.2010
86. Wierinckx, A. et al. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol. 21, 533-543 (.2011
87. Zemmoura, I. et al. Aggressive and malignant prolactin pituitary tumors: Pathological diagnosis and patient management. Pituitary 16, 515-522 (.2013
88. Thapar, K. et al. Overexpression of the growth-hormone-releasing hormone gene in acromegaly-Associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am. J. Pathol. 151, 769-784 (.1997
89. Gadelha, M. R., Trivellin, G., Hernandez Ramirez, L. C. & Korbonits, M. Genetics of pituitary adenomas. Front. Horm. Res. 41, 111-140 (.2013
90. Trouillas, J. et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (.MEN1): A case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am. J. Surg. Pathol. 32, 534-543 (.2008
91. Syro, L. V. et al. Pituitary tumors in patients with MEN1 syndrome. Clinics 67 (.Suppl. 1), 43-48 (.2012
92. Toledo, S. P., Lourenco, D. M. Jr & Toledo, R. A. A differential diagnosis of inherited endocrine tumors and their tumor counterparts. Clinics (Sao Paulo) 68, 1039-1056 (2013
93. Beckers, A., Aaltonen, L. A., Daly, A. F. & Karhu, A. Familial isolated pituitary adenomas (.FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (.AIP) gene. Endocr. Rev. 34, 239-277 (.2013
94. Pivonello, R. et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J. Clin. Endocrinol. Metab. 89, 4493-4502 (.2004
95. Gagliano, T. et al. Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 16, 91-100 (.2013
96. Molitch, M. E. Management of medically refractory prolactinoma. J. Neurooncol. http://dx.doi.org/10.1007/s11060-013-1270-1278.
97. Gillam, M. P., Molitch, M. P., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485-534 (.2006
98. Oh, M. C. & Aghi, M. K. Dopamine agonist-resistant prolactinomas. J. Neurosurg. 114, 1369-1379 (.2011
99. Melmed, S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189-3202 (.2009
100. Kreutzer, J., Vance, M. L., Lopes, M. B. & Laws, E. R. Jr. Surgical management of GH-secreting pituitary adenomas: An outcome study using modern remission criteria. J. Clin. Endocrinol. Metab. 86, 4072-4077 (.2001
101. Wilson, T. J., McKean, E. L., Barkan, A. L., Chandler, W. F. & Sullivan, S. E. Repeat endoscopic transsphenoidal surgery for acromegaly: Remission and complications. Pituitary 16, 459-464 (.2013
102. Melmed, S. et al. Acromegaly Consensus Group. Guidelines for acromegaly management: An update. J. Clin. Endocrinol. Metab. 94, 1509-1517 (.2009
103. Gola, M., Bonadonna, S., Mazziotti, G., Amato, G. & Giustina, A. Resistance to somatostatin analogs in acromegaly: An evolving concept? J. Endocrinol. Invest. 29, 86-93 (.2006
104. Colao, A., Auriemma, R. S., Lombardi, G. & Pivonello, R. Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32, 247-271 (.2011
105. Fougner, S. L., Casar-Borota, O., Heck, A., Berg, J. P. & Bollerslev, J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76, 96-102 (.2012
106. Kato, M. et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr. J. 59, 221-228 (.2012
107. Kopchick, J. J., Parkinson, C., Stevens, E. C. & Trainer, P. J. Growth hormone receptor antagonists: Discovery, development and use in patients with acromegaly. Endocr. Rev. 23, 623-646 (.2002
108. Parkinson, C. & Trainer, D. J. The place of pegvisomant in the management of acromegaly. Endocrinologist 13, 408-416 (.2003
109. Paisley, A. N. & Drake, W. H. Treatment of pituitary tumors. Pegvisomant. Endocrine 28, 111-114 (.2005
110. Kovacs, K. & Horvath, E. Effects of medical therapy on pituitary tumors. Ultrastruct. Pathol. 29, 163-167 (.2005
111. Drake, W. M., Berney, D. M., Kovacs, K. & Monson, J. P. Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Eur. J. Endocrinol. 153, 203-205 (.2005
112. Horvath, E. & Kovacs, K. Pathology of acromegaly. Neuroendocrinology 83, 161-165 (.2006
113. Van der Lely et al. Long-Term safety of pegvisomant in patients with acromegaly: Comphrensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97, 1589-1597 (.2012
114. Fleseriu, M & Petersen, S. Medical management of Cushing's disease: What is the future? Pituitary 15, 330-341 (.2012
115. Colao, A., Boscaro, M., Ferone, D. & Casanueva, F. F. Managing Cushing's disease: The state of the art. Endocrine http://dx.doi.org/10.1007/ s12020-013-0129-0122.
116. Pollock, B. E. & Young, W. F. Jr. Stereotactic radiosurgery for patients with ACTH-producing pituitary adenomas after prior adrenalectomy. Int. J. Radiat. Oncol. Biol. Phys. 54, 839-841 (.2002
117. Vik-Mo, E. O. et al. γ knife stereotactic radiosurgery of Nelson syndrome. Eur. J. Endocrinol. 160, 143-148 (.2009
118. Petit, J. H. et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J. Clin. Endocrinol. Metab. 93, 393-399 (.2008
119. Banasiak, M. J. & Malek, A. R. Nelson syndrome: Comprehensive review of pathophysiology, diagnosis, and management. Neurosurg. Focus 23, E13 (.2007
120. Wagenmakers, M. A. et al. Endoscopic transsphenoidal pituitary surgery: A good and safe primary treatment option for Cushing's disease, even in case of macroadenomas or invasive adenomas. Eur. J. Endocrinol. 169, 329-337 (.2013
121. Pereira, A. M. & Biermasz, N. R. Treatment of nonfunctioning pituitary adenomas: What were the contributions of the last 10 years? A critical view. Ann. Endocrinol. (Paris) 73, 111-116 (2012
122. Ding, D., Starke, R. M. & Sheehan, J. P. Treatment paradigms for pituitary adenomas: Defining the roles of radiosurgery and radiation therapy. J. Neurooncol. http://dx.doi.org/10.1007/s11060-013-1262-1268.
123. Castinetti, F. et al. Outcome of γ knife radiosurgery in 82 patients with acromegaly: Correlation with initial hypersecretion. Clin. Endocrinol. Metab. 90, 4483-4488 (.2005
124. Prasad, D. Clinical results of conformal radiotherapy and radiosurgery for pituitary adenoma. Neurosurg. Clin. N. Am. 17, 129-141 (.2006
125. Verma, J., McCutcheon, I. E., Waguespack, S. G. & Mahajan, A. Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas. Pituitary http://dx.doi.org/10.1007/s11102-013-0541-x.
126. Castinetti, F., Regis, J., Dufour, H. & Brue, T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat. Rev. Endocrinol. 6, 214-223 (.2010
127. Minniti, G. et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: Update after an additional 10 years. J. Clin. Endocrinol. Metab. 90, 800-804 (.2005
128. MacLean, J., Aldridge, M., Bomanji, J., Short, S. & Fersht, N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: Variable clinical response in preliminary evaluation. Pituitary http://dx.doi.org/10.1007/s11102-013-0540-y.
129. Mrugala, M. M. & Chamberlain, M. C. Mechanisms of disease: Temozolomide and glioblastoma - look to the future. Nat. Clin. Pract. Oncol. 5, 476-486 (.2008
130. Stupp, R., van den Bent, M. J. & Hegi, M. E. Optimal role of temozolomide in the treatment of malignant gliomas. Curr. Neurol. Neurosci. Rep. 5, 198-206 (.2005
131. Salehi. F. et al. O-6 methylguanine-DNA methyltransferase (.MGMT) immunohistochemical expression in pituitary cortocotroph adenomas. Neurosurgery 70, 491-496 (.2012
132. Kovacs, K. et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 115, 261-262 (.2008
133. Ortiz, L. D. et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (.Sao Paulo) 67 (.Suppl. 1), 119-123 (.2012
134. Syro, L. V. et al. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin. Endocrinol. (.Oxf.) 65, 552-553 (.2006
135. Kovacs, K. et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum. Pathol. 38, 185-189 (.2007
136. Syro, L. V. et al. Treatment of pituitary neoplasms with temozolomide: A review. Cancer 117, 454-462 (.2011
137. Moshkin, O. et al. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: The role of temozolomide therapy. Hormones (Athens) 10, 162-167 (2011
138. Ortiz, L. D. et al. Anti-VEGF therapy in pituitary carcinoma. Pituitary 15, 445-449 (.2012
139. Bode, H. et al. SOM230 (.pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp. Clin. Endocrinol. Diabetes 118, 760-763 (.2010
140. Zacharia, B. E. et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing's disease from capecitabine and temozolomide (.CAPTEM): A case series. Neurosurgery 74, E447-E455 (.2014
141. Jouanneau, E. et al. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15, 37-43 (.2012
142. Fukuoka, H. et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J. Clin. Invest. 121, 4712-4721 (.2011
143. Fukuoka, H. et al. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: Strategy for targeted prolactinoma therapy. Mol. Endocrinol. 25, 92-103 (.2011.